Minalrestat

This classification denotes an aldose reductase inhibitor with the molecular formula C19H11BrF2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G44PE6QB31, chemically known as 2-((4-bromo-2-fluorophenyl)methyl)-6-fluorospiro(isoquinoline-4(1h),3-pyrrolidine)-1,2,3,5(2h)-tetrone but generally known as minalrestat, which bears US NIH Compound Identifier 190816. European Medicines Agency schedules Minalrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08972MIG. The term MINALRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). MINALRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule minalrestat under HS 29251995 and SITC 51482. As of Q4 2014, MINALRESTAT remains the US FDA Preferred Term for this commodity. Minalrestat bears US NLM identifiers UMLS ID C1175807 and NCI Concept Code C72820. SMILES: BRC1CC(F)C(CN2C(=O)C3(CC(=O)NC3=O)C3C(C2=O)CCC(F)C3)CC1.